Acute Care Therapeutics for Surgical Settings

Baudax Bio is a pharmaceutical company focused on developing and commercializing innovative products for acute care settings.

About Baudax Bio

We are committed to bringing meaningful therapeutic options to patients, healthcare providers, and payers.  We currently have multiple therapeutic candidates across early, mid and late-stage clinical development, including a FDA approved non-opioid therapy for use in the acute care setting.

About Us

Our Innovative Portfolio & Pipeline

On February 20, 2020, the FDA approved ANJESO (meloxicam) injection, for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics.  Our product pipeline contains valuable therapeutic candidates for patients and healthcare providers in acute care settings.

ANJESO (meloxicam) injection

Product Portfolio

Latest News

Baudax Bio Announces Partial Adjournment of Annual Meeting of Shareholders

View Press Release

Baudax Bio Announces Partial Adjournment of Annual Meeting of Shareholders

View Press Release

Baudax Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

View Press Release

Baudax Bio to Participate at the Oppenheimer 31st Annual Healthcare Conference

View Press Release

Baudax Bio Strengthens Management Team with Appointment of Richard S. Casten as Chief Financial Officer

View Press Release

Baudax Bio to Present at the H.C. Wainwright Global Life Sciences Conference

View Press Release

Baudax Bio Reports 2020 Annual Financial Results

View Press Release

Baudax Bio to Report 2020 Annual Financial Results and Host Conference Call and Webcast on February 16, 2021

View Press Release

Baudax Bio Announces $17.6 Million Offering Priced At-the-Market under Nasdaq Rules

View Press Release

Baudax Bio Announces Exercise of Warrants for Gross Proceeds of $13.4 Million

View Press Release

Email Alerts

Stay informed and receive company updates straight to your inbox.

Sign up today